TP53 and hepatocellular carcinoma: Our IPA results predict that FXYD5 expression may be upregulated through the activation of major oncogenes (e.g., CTNNB1, MET, and TERT) and the loss of tumor suppressors (e.g., TP53 and AXIN1), suggesting that dysadherin upregulation could represent a convergent outcome of primary driver mutations in HCC (Supplementary Fig. 7i).